Surgical and Perioperative Treatments for Esophagogastric Junction Cancer

Overview

Journal Ann Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2024 Jun 5

PMID 38839368

Authors

Yoshitomo Yanagimoto

Yukinori Kurokawa

Yuichiro Doki

Affiliations

Soon will be listed here.

Abstract

Esophagogastric junction cancer (EGJC) is a rare malignant disease that occurs in the gastroesophageal transition zone. In recent years, its incidence has been rapidly increasing not only in Western countries but also in East Asia, and it has been attracting the attention of both clinicians and researchers. EGJC has a worse prognosis than gastric cancer (GC) and is characterized by complex lymphatic drainage pathways in the mediastinal and abdominal regions. EGJC was previously treated in the same way as GC or esophageal cancer, but, in recent years, it has been treated as an independent malignant disease, and treatment focusing only on EGJC has been developed. A recent multicenter prospective study revealed the frequency of lymph node metastasis by station and established the optimal extent of lymph node dissection. In perioperative treatment, the combination of multi-drug chemotherapy, radiation therapy, molecular targeted therapy, and immunotherapy is expected to improve the prognosis. In this review, we summarize previous clinical trials and their important evidence on surgical and perioperative treatments for EGJC.

References

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2022; 26(1):1-25. DOI: 10.1007/s10120-022-01331-8. View

A von Dobeln G, Klevebro F, Jacobsen A, Johannessen H, Nielsen N, Johnsen G . Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus. 2018; 32(2). DOI: 10.1093/dote/doy078. View

Kusano C, Gotoda T, Khor C, Katai H, Kato H, Taniguchi H . Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2009; 23(11):1662-5. DOI: 10.1111/j.1440-1746.2008.05572.x. View

Pedrazzani C, De Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi A . Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007; 134(2):378-85. DOI: 10.1016/j.jtcvs.2007.03.034. View

Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M . Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2016; 20(Suppl 1):69-83. DOI: 10.1007/s10120-016-0663-8. View

Omloo J, Lagarde S, Hulscher J, Reitsma J, Fockens P, van Dekken H . Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007; 246(6):992-1000. DOI: 10.1097/SLA.0b013e31815c4037. View

Hagens E, van Berge Henegouwen M, van Sandick J, Cuesta M, van der Peet D, Heisterkamp J . Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer. 2019; 19(1):662. PMC: 6610993. DOI: 10.1186/s12885-019-5761-7. View

Stahl M, Walz M, Stuschke M, Lehmann N, Meyer H, Riera-Knorrenschild J . Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27(6):851-6. DOI: 10.1200/JCO.2008.17.0506. View

10.

Sugano K, Spechler S, El-Omar E, McColl K, Takubo K, Gotoda T . Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut. 2022; 71(8):1488-1514. PMC: 9279854. DOI: 10.1136/gutjnl-2022-327281. View

11.

Tagkalos E, van der Sluis P, Berlth F, Poplawski A, Hadzijusufovic E, Lang H . Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial). BMC Cancer. 2021; 21(1):1060. PMC: 8474742. DOI: 10.1186/s12885-021-08780-x. View

12.

Imamura Y, Watanabe M, Oki E, Morita M, Baba H . Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg. 2021; 5(1):46-59. PMC: 7832959. DOI: 10.1002/ags3.12406. View

13.

Kang Y, Yook J, Park Y, Lee J, Kim Y, Kim J . PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39(26):2903-2913. PMC: 8425847. DOI: 10.1200/JCO.20.02914. View

14.

Matsuno K, Ishihara R, Ohmori M, Iwagami H, Shichijyo S, Maekawa A . Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. J Gastroenterol. 2019; 54(9):784-791. DOI: 10.1007/s00535-019-01577-7. View

15.

Kita R, Yanagimoto Y, Imazeki H, Booka E, Tsushima T, Mizusawa J . Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2023; 54(2):206-211. DOI: 10.1093/jjco/hyad149. View

16.

Mine S, Tanaka K, Kawachi H, Shirakawa Y, Kitagawa Y, Toh Y . Japanese Classification of Esophageal Cancer, 12th Edition: Part I. Esophagus. 2024; 21(3):179-215. PMC: 11199297. DOI: 10.1007/s10388-024-01054-y. View

17.

Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F . Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. Gastric Cancer. 2024; 27(3):401-425. PMC: 11016517. DOI: 10.1007/s10120-023-01457-3. View

18.

Hulscher J, van Sandick J, de Boer A, Wijnhoven B, Tijssen J, Fockens P . Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002; 347(21):1662-9. DOI: 10.1056/NEJMoa022343. View

19.

Klevebro F, Johnsen G, Johnson E, Viste A, Myrnas T, Szabo E . Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015; 41(7):920-6. DOI: 10.1016/j.ejso.2015.03.226. View

20.

Kurokawa Y, Kawase T, Takeno A, Furukawa H, Yoshioka R, Saito T . Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg. 2023; 7(2):247-254. PMC: 10043771. DOI: 10.1002/ags3.12632. View